ClinicalTrials.gg
CompletedNCT03019887Updated Sep 9, 2021Results posted

Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

An interventional study of reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine in Schizophrenia Relapse, sponsored by Juntendo University. Completed. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-09-09.

Sponsored by Juntendo University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Study summary

To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.

Read the detailed description

We attempted to reduce the dose of antipsychotics to ≤1000-mg chlorpromazine eq./day. The dose was gradually reduced at a rate of ≤50-mg chlorpromazine eq./week, and the reduction was discontinued if the subjects relapsed. The differences in baseline cognitive function were analyzed between the patients with no relapse and relapse groups.

02

Conditions studied

  • Schizophrenia Relapse

Browse trials for

03

In context

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

This study's enrollment of 139 is above the median of 70 across 2,952 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Juntendo University is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • inpatients with a diagnosis of schizophrenia, and
  • those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000-mg chlorpromazine eq./day.

Exclusion criteria

Exclusion Criteria:

  • mental retardation,
  • substance abuse or dependence,
  • a history of major head trauma,
  • serious medical or neurological disorders, or
  • depot antipsychotic injections within the previous 3 months and electroconvulsive therapy within the previous 6 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    reduction group

    dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week

    Drug: reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine

Interventions

  • Drugreduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
06

What researchers measure

Primary outcomes

  1. Number of Participants With Relapse

    The definition of relapse is as follows 1.50% or greater increase in total DIEPSS score, 2. an increase in the total PANSS score of 25% or more from baseline, 3. deliberate self-injury, 4. emergence of clinically significant suicidal ideation, 5. violent behavior resulting in clinically significant injury to another person or property damage.

    Time frame: One year after the baseline cognitive function test or three months after the end of dose reduction, whichever came first.

07

Results

Posted Sep 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneDose Reduction
Started139
Completed130
Not completed9

Outcome measures

PrimaryNumber of Participants With Relapse

The definition of relapse is as follows 1.50% or greater increase in total DIEPSS score, 2. an increase in the total PANSS score of 25% or more from baseline, 3. deliberate self-injury, 4. emergence of clinically significant suicidal ideation, 5. violent behavior resulting in clinically significant injury to another person or property damage.

Time frame:
One year after the baseline cognitive function test or three months after the end of dose reduction, whichever came first.
Reported as:
Count of participants · Participants
Number of Participants With Relapse
ParticipantsDose Reduction
Number of Participants With Relapse130

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Reduction—0/130 (0%)51/130 (39.2%)
Most frequent other events
Most frequent other events
EventDose Reduction
increase in the total PANSS score from baselinePsychiatric disorders51/130
violent behaviorPsychiatric disorders15/130
increase in total DIEPSS scorePsychiatric disorders0/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)Reduction Group
Mean51.5 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Reduction Group
Female50
Male80
Region of Enrollment
Region of Enrollment(participants)Reduction Group
Japan130
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2021, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2017
First posted
Jan 13, 2017
Start
Apr 2011
Primary completionActual
Jan 2017
CompletionActual
Jan 2017
Results first posted
Sep 9, 2021
Last update
Sep 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03019887
Lead sponsor
Juntendo University
Responsible party
Ryota Ataniya (Clinician, graduate student, Juntendo University) — Principal investigator
First posted
Jan 13, 2017
Start date
Apr 2011
Primary completion
Jan 2017
Completion
Jan 2017
Results posted
Sep 9, 2021
Last update
Sep 9, 2021

Study contacts

Takahashi Tadashi
study chair · Okada hospital
Mikiro Saito
study chair · Okada hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion